anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: AZD8529
Trial phase: Phase 2
SMILES: Cc1cc(-c2nc(CN3CCNCC3)no2)cc2c1C(=O)N(Cc1ccc(OC(F)(F)F)cc1)C2
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 110
Group description: Participants received AZD8529 40 mg capsule orally once daily for 13 weeks
Eligibility criteria:
Inclusion Criteria:

Be a female smoker between the ages of 18 to 75 years.
Want to quit smoking.
Be currently (last 30 days) smoking 10 or more cigarettes per day and report less than 3 months of consecutive smoking abstinence during the past year.
Be able, in the opinion of the site investigator (SI), to understand and follow all protocol-specified instructions and understand and provide written informed consent.
Be willing to provide personal information for entry into a clinical trial registry.
Agree to use and continue using at least one acceptable contraceptive method (oral contraceptives, IUDs, contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide, condoms with spermicide, or abstinence) or, if not of childbearing potential, must fulfill one of the following criteria at screening: post-menopausal defined as amenorrhea for at least 12 months and with follicle stimulating hormone (FSH) levels in the laboratory defined post-menopausal range and/or documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy or tubal ligation verified by the Site Investigator.
Agree not to use any other smoking behavioral intervention (self-help or formal treatment), acupuncture, or other smoking cessation pharmacotherapy during the study.
Agree to refrain from using dietary/herbal supplements other than vitamins and minerals for 7 days prior to receiving study drug and throughout the 13-week treatment period.
Agree to attend all required clinic appointments (including 3 eye exams) during the course of the 19-week study.

Exclusion Criteria:

Please contact the site for more information
Intervention: Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, (3-chloropropyl) ester
Trial phase: Phase 1 | Phase 2
SMILES: O=P(NCCCO)(OCCCCl)N(CCCl)CCCl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.

Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination.

Vofatamab
Eligibility criteria:
Key Disease Specific Inclusion Criteria:

Stage IV, locally advanced or metastatic (T4b, any N; or any T, N2-3) urothelial bladder cancer or TCC arising in another location of the urinary tract, including urethra, ureter, and renal pelvis
Histological or cytological diagnosis of UCC.
Relapsed after or are refractory to at least one prior line of chemotherapy which has not included a taxane (with the exception of Cohort 3 of Phase 2 and Phase 2b Monotherapy Expansion of Phase 2b which will allow the enrollment of patients with prior treatment with a taxane)
Subjects must have received at least one prior chemotherapeutic regimen (at least one cycle each) for advanced or metastatic/recurrent disease, of which at least one regimen included a platinum agent (unless contraindicated).
Prior neoadjuvant or adjuvant chemotherapy (without a taxane, except Cohort 3 of Phase 2 and Phase 2b Monotherapy Expansion, which will allow the enrollment of subjects with prior treatment with a taxane) is permitted and will not be counted as first-line chemotherapy, as long as the subject has not progressed within 12 months of the last dose.
Measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

Phase 2 and Phase 2b Specific Inclusion Criteria:

Patient must be confirmed to have a FGFR3 genomic alteration at the time of documentation of advanced disease.
Relapsed after or are refractory to an immune checkpoint inhibitor. This inclusion criterion does not apply if the checkpoint inhibitor is contraindicated.

Main Exclusion Criteria:

Prior anti-cancer therapy within 2 weeks prior to Cycle 1, Day 1
Prior treatment with an inhibitor that is targeted primarily to FGFRs
Clinically significant comorbid medical conditions or lab abnormalities
History of major bleeding (requiring a blood transfusion ≥ 2 units) not related to a tumor within the past 12 months
History of clinically significant coagulation or platelet disorder in the past 12 months
Currently receiving anticoagulation treatment
Incomplete healing from wounds from prior surgery
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at screening
Presence of positive test results for Hepatitis B or Hepatitis C
Known history of human immunodeficiency virus (HIV) seropositive status
Intervention: Voxilaprevir
Trial phase: Phase 1
ATC code: J05AP56
SMILES: CC[C@@H]1[C@@H]2CN(C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]3C[C@H]3CCCCC(F)(F)c3nc4ccc(OC)cc4nc3O2)[C@@H]1C(=O)N[C@]1(C(=O)NS(=O)(=O)C2(C)CC2)C[C@H]1C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Participants with matched normal renal function received a single dose voxilaprevir of 100 mg tablet orally on Day 1.
Eligibility criteria:
Key Inclusion Criteria:

All individuals:

Screening laboratory values within defined thresholds for group
Use of two effective contraception methods if female of childbearing potential or sexually active male

For individuals with severe renal impairment:

Stable chronic kidney disease
Creatinine clearance (CLcr) < 30 mL/min

Key Exclusion Criteria:

All individuals:

Pregnant or nursing female or male with pregnant female partner
Hepatitis B virus, hepatitis C virus (HCV) or HIV infection
History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol

For individuals with severe renal impairment:

Anticipated to require dialysis within 90 days of study dosing

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Sitagliptin phosphate monohydrate
Trial phase: Phase 4
SMILES: NC(CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F.O.O=P(O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days

Sitaglitpin: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
Eligibility criteria:
Inclusion Criteria:

Individuals of 18-70 years of age,
with Type 2 Diabetes,
with an HbA1c (6.5%-9%),
and with a systolic blood pressure (120-160 mmHg).

Exclusion Criteria:

Individuals with:

Type 1 Diabetes,
eGFR <50mL/min/1.73m,
pregnancy or breast feeding,
significant cardiac, pulmonary or liver disease,
prior history of pancreatitis, medullary thyroid cancer, multiple endocrine neoplasia syndromes,
SBP >161 mmHg, 7) DBP >100 mmHg,
alcohol or substance abuse,
states of secondary hypertension.
Intervention: Apixaban
Trial phase: Phase 4
ATC code: B01AF02
SMILES: COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.

Apixaban: New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
Eligibility criteria:
Inclusion Criteria:

Men or women, 18 to 65 years old with a BMI of 35 kg/m2 or greater who will be undergoing bariatric surgery (VSG and RYGB)
Signed written informed consent
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug
Women must not be breastfeeding

Exclusion Criteria:

History of documented clotting/coagulation disorder
History of cancer (within the last year)
Any diagnosis requiring anti-coagulation
History of hypersensitivity reaction to apixaban
Active clinically significant bleeding
Creatinine > 1.5 mg/dL
Participants currently receiving any type of anticoagulation or blood thinning medications, including heparin, low molecular weight heparins, Plavix, aspirin, NSAIDS

Participant who is taking any of the excluded medications

Combined P-glycoprotein and strong cytochrome P450 (CYP) 3A4 inhibitor
Combined P-glycoprotein and moderate CYP 3A4 inhibitor
Combined P-glycoprotein inducer and strong CYP 3A4 inducer
Inducers of p-glycoprotein
Strong inducers of CYP 3A4
Intervention: TESTOSTERONE CYPIONATE
Trial phase: Phase 4
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](OC(=O)CCC3CCCC3)CC[C@@]21[H]
Sex: Male
Age groups: Child
Healthy volunteers: No
Participants at risk: 10
Group description: Testosterone cypionate (200 mg/ml) intramuscular injection

testosterone cypionate 200mg/ml: Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
Eligibility criteria:
Inclusion Criteria:

Male infants with 47,XXY karyotype

Exclusion Criteria:

Gestational age at birth <36 weeks
Birth weight <5%ile or >95% for gestational age
History of thrombosis in a first degree relative
Exposure to androgen therapy outside of the study protocol.
Intervention: Methergine
Trial phase: Phase 4
ATC code: G02AB01
SMILES: CCC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 140
Group description: Methergine group
Eligibility criteria:
Inclusion Criteria:

Between 20 wks 0 days gestation and 24 wks 0 days gestation
English or Spanish speaking
BP before injection 140/90 or below
18 years old or over

Exclusion criteria:

hypertension either on the preoperative or operative day (defined as systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg)
D&E procedures with more than one day of cervical preparation with dilators
use of protease inhibitors
known coagulopathy
known morbidly adherent placenta
Intervention: Injectafer
Trial phase: Phase 2
SMILES: O.O=C([O-])C(O)C(O)C(OC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3O)C(O)C2O)C(O)C1O)C(O)CO.[Fe+3].[O-2].[OH-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: 15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute

Injectafer
Eligibility criteria:
Inclusion Criteria:

Male or female subject's ≥ 18 years of age, able to give informed consent to the study.
Fibromyalgia diagnosis based on The 2011 modification of the American College of Rheumatology (ACR) 's 2010 preliminary criteria for diagnosing fibromyalgia (2011ModCr)
A baseline score ≥ 60 on the FIQR
Subject's current medications to treat fibromyalgia, including pain medicines, anti-depressants, sleep medications must be on a stable dose for at least 30 days.
Subject's current narcotic medication must be on a stable dose for at least 30 days prior to randomization
Subjects at risk for pregnancy must have a negative pregnancy test at baseline and be practicing an acceptable form of birth control: have had a hysterectomy or tubal ligation, or otherwise be incapable of pregnancy, or have practiced any of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.

Exclusion Criteria:

Parenteral iron use within 4 weeks prior to screening.
History of > 10 blood transfusions in the past 2 years.
Anticipated need for blood transfusion during the study.
Known hypersensitivity reaction to any component of Injectafer® (Ferric Carboxymaltose).
Current or acute or chronic infection other than viral upper respiratory tract infection
Malignancy (other than basal or squamous cell skin cancer or the subject has been cancer free for ≥ 5 years).
Active inflammatory arthritis (e.g. rheumatoid arthritis, SLE).
Pregnant or lactating women.
Severe peripheral vascular disease with significant skin changes.
Seizure disorder currently being treated with medication.
Baseline ferritin ≥ 50 ng/mL.
Baseline TSAT ≥ 20%.
History of hemochromatosis or hemosiderosis or other iron storage disorders.
Known positive hepatitis with evidence of active disease.
Hemoglobin greater than the upper limit of normal.
Calcium or phosphorous outside the normal range.
Known positive hepatitis B antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis (i.e., AST/ALT greater than the upper limit of normal).
Known positive HIV-1/HIV-2 antibodies (anti-HIV)
Received an investigational drug within 30 days before randomization.
Chronic alcohol or drug abuse within the past 6 months.
Any other pre-existing laboratory abnormality, medical condition or disease which in view of the investigator participation in this study may put the subject at risk.
Subject unable to comply with the study requirements.
Intervention: ASPIRIN
Trial phase: Not Applicable
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: Female
Age groups: Adult
Healthy volunteers: No
Participants at risk: 5943
Group description: Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA.
Eligibility criteria:
Inclusion Criteria:

Nulliparous women between 18 - 40 years of age. Minors who are ≥ 14 years of age may be enrolled if permitted by the country's ethical guidelines.
No more than two previous first trimester pregnancy losses
No medical contraindications to aspirin;
Single live intrauterine pregnancy (IUP) between 6 0/7 and 13 6/7 weeks GA corroborated by an early dating ultrasound and with presence of a heartbeat.

Exclusion Criteria:

Women prescribed daily aspirin for more than 7 days;
Multiple gestations;
Fetal anomaly by ultrasound (Note most fetal anomalies are not detectable by ultrasounds done at this early gestation. Subsequent discovery of a fetal anomaly is not viewed as an exclusion.);
Hemoglobin < 7.0 gm/dl at screening;
Any other medical conditions that may be considered a contraindication per the judgment of the site investigator (e.g., Lupus, Type 1 Diabetes, or any other known significant disease)
Blood pressure ≥ 140/90 (Systolic blood pressure ≥ 140 and diastolic ≥ 90 at screening)
Intervention: Betamethasone
Trial phase: Phase 2
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days

Dexamethasone: oral dexamethasone 4 mg bid for 14 days
Eligibility criteria:
Inclusion Criteria:

confirmation of head & neck cancer (stage I-IV) or non-small cell lung cancer (stage II & III)
Undergoing treatment with either radiation alone or in combination with chemotherapy
Normal cognition and willingness to complete fatigue and quality of life forms, patient observation form, and pill diary

Exclusion Criteria:

Hypersensitivity to dexamethasone or corticosteroids or Equal sugar substitute
Corticosteroid within the past 30 days prior to study enrollment for greater than one week duration
Planned Stereotactic Body Radiation Therapy (SBRT)
Active psychosis
Current pregnancy
Active peptic ulcer disease or evidence of gastrointestinal bleed
Current active tuberculosis or systemic fungal infection
Previous diagnosis of diabetes mellitus
Acute febrile illness
Known human immunodeficiency virus or acquired immunodeficiency syndrome
Major surgery within two weeks of study enrollment of which the patient has not recovered
Psychostimulant use in the past 30 days prior to registration
History of phenylketonuria (PKU)
Intervention: Gadoterate Meglumine
Trial phase: Phase 4
SMILES: CNCC(O)C(O)C(O)C(O)CO.O=C([O-])CN1CCN(CC(=O)[O-])CCN(CC(=O)O)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 45
Group description: Subjects receiving a single intravenous injection of 0.1 mmol/kg body weight of DOTAREM
Eligibility criteria:
Inclusion Criteria:

Pediatric subject aged <2 years (term newborn infants to toddlers 23 months of age inclusive). Term is defined as ≥37 weeks of amenorrhea
Subject is scheduled to undergo routine gadolinium-enhanced MRI of any body region (e.g. CNS, cardiac) at the dose of 0.1 mmol/kg BW (0.2 mL/kg BW)
Subject with normal renal function for its age, estimated glomerular filtration rate calculated based on the Schwartz formula

Exclusion Criteria:

Subject planned for intervention (e.g. surgery) between the screening visit and up to 24 hours after DOTAREM injection
Subject whose preceding or subsequent treatment to DOTAREM injection (e.g., blood loss or receiving blood, treatment with diuretics, etc…) would alter DOTAREM pharmacokinetics parameters
Subject with subsequent planned treatment after DOTAREM injection that would prevent obtaining the required blood samples (e.g., emergency surgery, etc…)
Subject with a history of a bleeding disorder
Subject with severe liver disease (Child's Pugh Classification B or greater or serum direct bilirubin greater than 0.3 mg/dL, age adjusted)
Subject with electrolyte or fluid imbalance that presents undue risk
Subject undergoing a change in chemotherapy within 48 hours prior to and up to 24 hours after DOTAREM injection
Subject who received or will receive any other contrast agent within 72 hours prior to DOTAREM injection or up to 24 hours after DOTAREM injection
Subject with contraindication for MRI such as iron metal implants (e.g. aneurysm clips)
Subject with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents
Subject having participated within 30 days in a clinical study involving an investigational drug or device
Subject planned to participate simultaneously to another clinical study
Intervention: Lovenox
Trial phase: Phase 2
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.

Enoxaparin: Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment using a clinical protocol developed with our inpatient pharmacists.
Eligibility criteria:
Inclusion Criteria:

Inclusion criteria will include:

adult (age ≥18) patients presenting for reconstructive surgery under general anesthesia.
expected post-operative stay will be at least three days to allow peak aFXa levels to be drawn.
eligible patients will include those having major reconstructive surgery.

Exclusion Criteria:

Exclusion criteria will include:

contraindication to use of enoxaparin,
intracranial bleeding/stroke,
hematoma or bleeding disorder,
known heparin-induced thrombocytopenia,
creatinine clearance ≤30mL/min,
serum creatinine >1.6mg/dL, or epidural anesthesia.
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 75
Group description: Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block

Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
Eligibility criteria:
Inclusion Criteria:

Elective shoulder arthroscopy under ropivacaine single-shot interscalene brachial plexus block anesthesia (rotator cuff repair and shoulder decompression)
ASA I-III
Age 18-80 years old

Exclusion Criteria:

Any contraindication to interscalene brachial plexus block anesthesia
Interscalene brachial plexus block failure
Known local anesthetics allergy
Dexamethasone allergy or intolerance
Any contraindication to acetaminophen
Any contraindication to morphine or hydromorphone
Brachial plexus neuropathies
Chronic pain syndrome other than shoulder pain
Routine use of opioid medication
Routine use of systemic corticosteroid
Pregnancy
Weight below 50 kilograms
Incapability to understand a numeric verbal pain scale
Incapability to consent
Patient refusal
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 75
Group description: Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block

Dexamethasone: After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
Eligibility criteria:
Inclusion Criteria:

Elective shoulder arthroscopy under ropivacaine single-shot interscalene brachial plexus block anesthesia (rotator cuff repair and shoulder decompression)
ASA I-III
Age 18-80 years old

Exclusion Criteria:

Any contraindication to interscalene brachial plexus block anesthesia
Interscalene brachial plexus block failure
Known local anesthetics allergy
Dexamethasone allergy or intolerance
Any contraindication to acetaminophen
Any contraindication to morphine or hydromorphone
Brachial plexus neuropathies
Chronic pain syndrome other than shoulder pain
Routine use of opioid medication
Routine use of systemic corticosteroid
Pregnancy
Weight below 50 kilograms
Incapability to understand a numeric verbal pain scale
Incapability to consent
Patient refusal